Owned by the Association for International Promotion & Study in Tumors (APSIT)
Targeting PHB1 to inhibit castration-resistant prostate cancer progression in vitro and in vivo
Castration-resistant prostate cancer (CRPC) is currently the main challenge for prostate cancer (PCa) treatment, and there is an urgent need to find novel therapeutic targets and drugs. Prohibitin (PHB1) is a ...